# A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

Source: https://onco.cc/trials/nct06966453/  
OnCo record `nct06966453` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Disitamab vedotin in advanced solid tumours, run by Pfizer, active and no longer recruiting.

## Summary

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer is a phase 1/2 interventional study registered as NCT06966453 by Pfizer, with 74 participants enrolled, started 2025-06-30 and due to reach its primary completion in 2027-10-25. Interventions recorded: Disitamab vedotin.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06966453
- Phase: 1/2
- Setting: A PHASE 1B/2, OPEN-LABEL, MULTICOHORT STUDY OF DISITAMAB VEDOTIN IN ADULTS WITH HER2 EXPRESSING ADVANCED BREAST CANCER
- Sponsor: Pfizer
- Enrolled: 74

## Sources

- ClinicalTrials.gov NCT06966453: https://clinicaltrials.gov/study/NCT06966453

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Disitamab vedotin](https://onco.cc/drugs/disitamab-vedotin/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct06966453.json